Sentences with phrase «studies of cell therapy»
Several previous studies of cell therapy for heart attack have used unsorted bone marrow cells.
http://www.emoryhealthsciblog.com/ Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The startup describes itself as a deep data platform for the study of exosomes, which are small lipid vesicles — air - or fluid - filled cavities — that are excreted from cells and which deliver information that Mantra plans to use to come up with new drug therapies.
Researchers at the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center at the University of Pennsylvania, study plants like this Arabidopsis thaliana to learn how molecules, cells and tissues integrate mechanics within plant and animal biology, with the aim of creating new materials, biomedical therapies and agricultural technologies.
«These findings stimulate new avenues for cell therapy approaches for regenerative medicine,» said Douglas Millay, PhD, study senior investigator and a scientist in the Division of Molecular Cardiovascular Biology at Cincinnati Children's.
A new study has identified a group of molecules in prostate - cancer cells that doctors might one day use to distinguish which patients should be treated with radiation therapy if rising PSA levels indicate their cancer has recurred after surgical removal of the prostate.
Based on results of the current study described in a report online June 18 in the journal Cancer Cell, Johns Hopkins researchers say they are planning a phase I clinical trial to test the paclitaxel - fostamatinib combination therapy in patients with recurrent advanced ovarian cancer.
Along with the study's co-first authors, Drs. Aayoung Hong and Gatien Moriceau, Lo hypothesized that if they could identify the key tumor cell processes triggered by withdrawal of MAPK inhibitors, then scientists can exploit these process with existing or investigational drugs to trigger the maximal levels of tumor cell death immediately following cessation of the initial therapy.
«Cultural revolution in the study of the gut microbiome: Human gut - on - a-chip technology used to co-culture gut microbiome, human intestinal cells could lead to new therapies for inflammatory bowel diseases.»
Led by researchers at the Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), the retrospective study suggested that a pattern of molecules called microRNA (miRNA) in tumor cells might predict patients» response to radiation therapy.
Now a University of Colorado Cancer Center study published online ahead of print in the journal Oncogene offers compelling evidence explaining this failure and offering a possible strategy for the use of retinoic acid or other retinoids against some breast cancers: Because early clinical trials are often offered to patients who have already tried other more established therapies, breast cancer cells may have been pushed past an important tipping point that offers retinoic acid resistance.
We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.
The study «provided the surprising result that one new therapy currently being explored to lower insulin resistance promotes, rather than decreases, the formation of bone in mice,» says Darwin Prockop, a stem cell researcher at Texas A&M College of Medicine in Temple, who was not involved in the work.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.
Frequent, low - dose chemotherapy regimens avoid this effect and may therefore be more effective at treating certain types of breast and pancreatic cancer, according to the murine study «Metronomic chemotherapy prevents therapy - induced stromal activation and induction of tumor - initiating cells,» which will be published online November 23 in The Journal of Experimental Medicine.
«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.
«Due to the inhibitory function of Treg cells, people have been trying to use these cells for therapy in human autoimmune diseases or transplantation,» explains professor Yun Cai Liu, Ph.D., who led the current study.
Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: «In an effort to better understand the role of HIF - 1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF - 1 inhibiting molecule when placed in a hypoxic environment.
«Cancer therapies that attack the lipid composition of the cell membrane would be an entirely new class of anticancer drugs,» says co-senior study author Paul Beales, of the University of Leeds in the UK.
«The discovery of the novel progenitor represents a fundamental advance in this field and potentially to the liver regeneration field using cell therapy,» said the study's senior author, Valerie Gouon - Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount Sicell therapy,» said the study's senior author, Valerie Gouon - Evans, PharmD, PhD, Assistant Professor, in the Department of Developmental and Regenerative Biology, Black Family Stem Cell Institute, at the Icahn School of Medicine at Mount SiCell Institute, at the Icahn School of Medicine at Mount Sinai.
Nevertheless,» [the] study is very important because it demonstrates for the first time that we can use gene therapy to transform cells in the brain into ones that will secrete GDNF,» says Jeffrey Kordower, a professor of neurological sciences at Rush Presbyterian Medical Center in Chicago.
In the current study, Dr. Xu and colleagues gave radiation therapy to a mouse model of human pancreatic cancer to eradicate the bulk tumors, while only the cancer stem cells remained in the residual scars.
In March 2016, Penn researchers published a study in Blood that showed long - term ibrutinib treatment reverses the dysfunction of T cells in CLL and that combining CAR therapy with ibrutinib enhanced engineered T cell proliferation in mice.
The targeted therapy everolimus may be safely combined with R - CHOP for new, untreated diffuse large B - cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology.
Delivering a single injection of a scar - busting gene therapy to the spinal cord of rats following injury promotes the survival of nerve cells and improves hind limb function within weeks, according to a study published April 2 in The Journal of Neuroscience.
Studying the vying for nutrients in the cell «will teach us really interesting biology about how the cell senses the presence of a parasite metabolically, and how the cell is able to metabolically respond,» Pernas says — knowledge that could lead to new therapies.
«Breast cancer stem cells pose a serious problem for therapy,» says lead study investigator Gregg Semenza, M.D., Ph.D., the C. Michael Armstrong Professor of Medicine, director of the Vascular Biology Program at the Johns Hopkins Institute for Cell Engineering and a member of the Johns Hopkins Kimmel Cancer Center.
We hope this leads to the ability to design, study and test new therapies for every patient on their own cells in the lab, leading to new treatments and breakthroughs in personalized medicine for individuals with a variety of lung diseases, including cystic fibrosis,» explained lead author Katherine McCauley, a PhD student at BUSM.
«This landmark study draws the conclusion in pre-clinical animal studies that stem cell therapy for disc degenerative disease might be a potentially effective treatment for the very common condition that affects people's quality of life and productivity,» said the senior author, Wenchun Qu, MD, PhD, of the Mayo Clinic in Rochester, Minn..
They also published findings from an animal study showing that the effect of stem cell therapy following heart attack is indirect — the stem cells themselves do not survive long after being placed in the heart, but they cause enduring effects by stimulating the rapid growth of surviving heart tissue and attracting stem cells already in the heart, which mature into functional heart cells.
Moreover, her studies are the first to indicate that therapies targeted at controlling the properties of smooth muscle cells within lesions may be highly effective in treating a disease that is the leading cause of death worldwide.
A drug approved in Europe to treat osteoporosis has now been shown to stop the growth of breast cancer cells, even in cancers that have become resistant to current targeted therapies, according to a Duke Cancer Institute study.
«By understanding how stress accelerates invasion in aggressive breast tumor cells, this work will inform future studies into whether beta - blockers could be a useful adjuvant therapy in the treatment of some aggressive breast cancers.»
The journal's home page explains that translational medicine «builds on basic research advances — studies of biological processes using cell cultures, for example, or animal models — and uses them to develop new therapies or medical procedures.»
«RYBP would make cancer cells more sensitive to DNA damage, which would make chemo or radiation therapy more effective,» said Mohammad Ali, a postdoctoral fellow and the lead author of the study.
A new study led by scientists from the Florida campus of The Scripps Research Institute (TSRI) sheds light on a signaling circuit in cells that drives therapy resistance in prostate cancer.
If these unheralded cells are as important as the authors suspect, studying them may open the door to new therapies for some forms of blindness.
«Uncovering why psoriasis recurs: Study identifies population of resident T cells that may initiate psoriasis and allow skin lesions to recur after therapy ends.»
Vanderbilt - led research, as part of an international, multicenter trial, found regular blood transfusion therapy significantly reduces the recurrence of silent strokes and strokes in children with sickle cell anemia who have had pre-existing silent strokes, according to study results released today in the New England Journal of Medicine (NEJM).
To fulfil the promise of stem cell therapy, it is important to discover the function of the respective stem cells and understand how they interact with their environment, that is, the surrounding cells and tissues,» explains Prof. Lohmann, who heads the Developmental Biology research group at the Centre for Organismal Studies (COS).
A study published January 4th in Cell Stem Cell demonstrates that a gene therapy approach can lead to the long - term survival of functional beta cells as well as normal blood glucose levels for an extended period of time in mice with diabetes.
One of the biggest challenges for medical researchers studying the effectiveness of stem cell therapies is that transplants or grafts of cells are often rejected by the hosts.
In a laboratory study in Oxford, researchers have shown how it might be possible to reverse blindness using gene therapy to reprogram cells at the back of the eye to become light sensitive.
Genetically modified «hunter» T cells successfully migrated to and penetrated a deadly type of brain tumor known as glioblastoma (GBM) in a clinical trial of the new therapy, but the cells triggered an immunosuppressive tumor microenvironment and faced a complex mutational landscape that will need to be overcome to better treat this aggressive cancer, Penn Medicine researchers report in a new study this week in Science Translational Medicine.
«The current study was designed to determine the effect of inhibition of platelet activation and function by aspirin therapy on colon and pancreatic cancer cell proliferation,» the researchers wrote.
«This groundbreaking study sets the stage for more exacting research, using the latest genomic technologies and aimed at developing new therapies that could help the tens of thousand of patients who urgently need our help,» said Dr. Nhan Tran, an Associate Professor of TGen's Cancer and Cell Biology Division and the study's other co-senior author.
«It's not yet clear whether or how GSK3 might be a target for future therapies for B cell - related diseases, but this research opens a lot of doors for further studies,» Rickert said.
«There was some skepticism about whether a CD19 - directed therapy would work in this disease, since nearly all of these patients» cancerous plasma cells do not express CD19,» said the study's senior author, Edward Stadtmauer, MD, chief of Hematologic Malignancies and a professor of Hematology / Oncology in Penn's Abramson Cancer Center and Perelman School of Medicine.
The team designed a different approach to study the therapy in myeloma, adding in an infusion of the patient's own stem cells along with their lymphodepleting chemotherapy (melphalan), followed by CTL019 infusion about two weeks later.